The development and use of the E75 (HER2 369-377) peptide vaccine

  • Future Oncol. 2016 Jun;12(11):1321-9. doi: 10.2217/fon-2015-0054.
Guy T Clifton  1 ,  George E Peoples  2 ,  Elizabeth A Mittendorf  3
Affiliations
  • 1. Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, Houston, TX 77030, USA.
  • 2. Cancer Vaccine Development Program, Metis Foundation, 600 Navarro Street, San Antonio, TX 78205, USA.
  • 3. Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1434, Houston, TX 77030, USA.
PMID: 27044454 DOI: 10.2217/fon-2015-0054
Abstract

E75 (nelipepimut-S) is an immunogenic peptide derived from the HER2 protein. When combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), nelipepimut-S has been used as a vaccine that is capable of eliciting a robust anti-HER2 immune response. Early-phase clinical trials that enrolled women with node-positive or high-risk node-negative breast Cancer who had been rendered disease free with standard of care therapy but were at risk for recurrence, demonstrated the vaccine to be safe with a suggestion of clinical benefit. Nelipepimut-S is currently being evaluated in a Phase III clinical trial. This article covers the preclinical and clinical development of nelipepimut-S.

Keywords
E75; breast cancer; cancer vaccine; nelipepimut-S; peptide.
Products